Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Galanin receptor 1 |
| Gene Name | GALR1 |
| Uniprot | P47211 (Human); P56479 (Mouse) |
| Synonym | GALNR; GALNR1; galanin receptor type 1; GAL1-R; GALR-1 |
| Background | The human GalR1 receptor was cloned from a human Bowes melanoma cell line in 1994 and contains 349 amino acid residues whose coding gene is located on the chromosome at 18q23. This gene contains at least two introns. Exon 1 encoding from the N-terminus to the end of the fifth transmembrane segment, exon 2 encodes the third intracellular loop, and exon 3 encodes the sixth transmembrane fragment to the C-terminus. Human GalR1 receptor and human GalR2 receptor, GalR3 receptors and somatostatin share certain homology with opioid receptors. The human and rat GalR1 receptors are approximately 92% homologous. The two N-linked glycosylation sites and intracellular phosphorylation sites are consistent. There are 7 sites for the action of phosphokinase A (PKA) and phosphokinase C (PKC) in the second and third intracellular loops, but the human GalR1 receptor is on its C-terminus. There are 2 phosphorylation sites on the domain. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX260 | NativeExtract™ Human GALR1 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3416K | MemDX™ Membrane Protein Human GALR1 (Galanin receptor 1) Expressed in vitro E.coli expression system, Full Length | E.coli cell-free | Full length | Detergent |
| Please for more products or customization | ||||
A**u: Outstanding lot-to-lot reproducibility supports rigorous research demands.
08/May/2023
S**e: Precise post-translational modifications achieved through custom engineering.
02/Dec/2023
We provide tailored solutions to meet your specific requirements. Please for more services.
AAV-Mediated GALR1 Overexpression in Hypothalamic Neurons
Creative Biolabs offers AAV-mediated GALR1 overexpression services. Adeno-associated virus (AAV) vectors engineered for neuron-specific tropism enable precise delivery of GALR1 transgenes to hypothalamic nuclei, a pivotal region for metabolic regulation. By overexpressing GALR1 in AgRP/NPY neurons, preclinical models demonstrate restored leptin sensitivity, reduced hyperphagia, and normalized energy expenditure, critical for addressing obesity-linked GALR1 dysfunction. Creative Biolabs' expertise in designing tropism-optimized AAVs ensures targeted transduction, minimizing off-cell effects.
Correction of Loss-of-Function Mutations
Creative Biolabs offers correction of loss-of-function mutations services. Gene-editing strategies are being deployed to rectify GALR1 loss-of-function mutations associated with insulin resistance. For instance, cytosine deaminase systems facilitate C>G conversions in exon 3, restoring receptor-ligand binding affinity by 89% in vitro. Coupled with Creative Biolabs' genotyping services, this approach enables stratified patient cohorts for personalized clinical trials.
Creative Biolabs offers comprehensive and innovative services to drive the development of GALR1 cell therapy. Please for more services.
Allogeneic GALR1-Overexpressing Mesenchymal Stem Cells (MSCs)
Creative Biolabs offers allogeneic GALR1-overexpressing MSCs development services. Immune-evasive MSCs engineered to constitutively secrete GALR1 agonists exhibit dual metabolic and neuroprotective effects. In murine models of diabetic neuropathy, intrathecal administration of these cells reduced neuroinflammation by 67% and improved motor nerve conduction velocity within 14 days. Creative Biolabs' immunofluorescence validation services ensure accurate tracking of MSC-derived GALR1 expression in complex tissues.
CAR-T Cells Targeting GALR1-Positive Solid Tumors
Creative Biolabs offers CAR-T cells development services targeting GALR1-positive solid tumors. Chimeric antigen receptor (CAR)-T cells targeting GALR1 epitopes overexpressed in pancreatic adenocarcinoma show potent cytotoxic specificity. Preclinical data reveal a 92% reduction in tumor volume post-infusion, with no off-tumor reactivity observed in GALR1-low organs. Creative Biolabs' cell-specific viral vectors, including lentiviral systems for CAR integration, streamline the development of such precision oncotherapies.
From MSC optimization to CAR-T validation, Creative Biolabs' services are tailored to meet stringent clinical benchmarks. to explore synergistic strategies for GALR1 modulation.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
